BOSTER
antibody and ELISA experts

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com

Anti-CTLA4 (CD152) Monoclonal Antibody

Catalog Number: M00020

Overview

Product Name	Anti-CTLA4 (CD152) Monoclonal Antibody
Reactive Species	Human, Mouse, Rat
Description	Boster Bio Anti-CTLA4 (CD152) Monoclonal Antibody catalog # M00020. Tested in WB, ICC/IF applications. This antibody reacts with Human, Mouse, Rat.
Application	IF, ICC, WB
Clonality	Monoclonal ADCD-3
Formulation	Rabbit IgG in stabilizing components, phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. *This antibody is supplied in a stabilized formulation. Compatibility with conjugation reactions depends on the chemistry of the conjugation method used. For conjugation methods that are not compatible with the stabilizing components present in this formulation, a carrier-free antibody format is required.
Storage Instructions	Store at -20°C for one year. For short term storage and frequent use, store at 4°C for up to one month. Avoid repeated freeze-thaw cycles.
Host	Rabbit
Uniprot ID	P16410

Technical Details

Immunogen	A synthesized peptide derived from human CTLA4 (CD152)
Isotype	Rabbit IgG
Form	Liquid
Concentration	0.5mg/ml
Purification	Affinity-chromatography
Suggested Dilutions	WB 1:500-2000 ICC/IF 1:50-200

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com

Anti-CTLA4 (CD152) Monoclonal Antibody (M00020) Images



All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.



HPM treatment restored body weight and increased spleen index in immunosuppressed rats. A Schematic diagram of the acupoints used in this experiment. B Dimensional specifications of the HPM in the experiment. C Schematic showing timeline for CTX induction, HPM treatment and behaviour experiments. D , E Mean weight of each group (n = 8 per each group). Data are expressed as means ± SD, One-way ANOVA tests with LSD-t post-hoc tests executed. * p



Immunosuppressed rats exhibit depressive/anxiety-like behavior, which is attenuated after HPM binding inhibitor treatment. A , B Schematic representation of OFT (n = 8 per each group). C , D Schematic representation of EPM (n = 5 per each group). Data were analyzed using Kruskal–Wallis H-statistic test. * p



The number of WBCs was significantly reduced in rats after cyclophosphamide injection and increased after HPM treatment. A WBCs and their subtype percentage results. (n = 3–8 per each group). B – D RBC, hemoglobin and platelet counts (n = 8 per each group). Data were analyzed using One-way ANOVA tests with LSD-t post-hoc tests executed. * p

Histological analysis of spleen in immunosuppressed rats (H&E staining, bar = 100 um). CV, central vein; LN, lymph nodule; MZ, marginal zone; RP, red pulp, NG: normal group; CTX: cyclophosphamide; HPM: Herb-partitioned moxibustion; aCD28: anti-CD28; aCTLA-4: anti-CTLA-4; LEV: Levamisole Index in PubMed under a CC BY license. PMID: 38369521

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com





Levels of CD28 (A), CTLA-4 (B), B7-1 (C), B7-2 (D), alpha-MSH (E), TrkB (F), 5-HT (G), BDNF (H) in serum of immunosuppressed rats (n = 8 per each group). Data are expressed as means ± SD, One-way ANOVA tests with LSD-t post-hoc tests executed. * p



Effect of HPM treatment on T lymphocytes in the spleens of immunosuppressed rats. A CD4+, CD8+ cells were gated by the protocol. B Flow cytometric identification of CD4 + , CD8 + cells in the spleen. C , D Absolute count statistics of CD4+, CD8+ cells between different groups in spleen tissue (n = 5 per each group). Data were analyzed using Kruskal–Wallis H-statistic test. ** p



Results of the CD28 mRNA level and correlation between CD28 and B7-1 in spleen of immunosuppressed rats (n = 3–5 per each group). A immunofluorescence results, a – f Pearson correlation scatterplot; B CD28 IOD results; C CD28 mRNA level; D CD28 and B7-1 colocalization results. Data are expressed as means ± SD, One-way ANOVA tests with LSD-t post-hoc tests executed and Pearson correlation coefficient, Kruskal–Wallis one-way ANOVA test. * p



Results of the correlation between CD28 and B7-2 in spleen of immunosuppressed rats (n = 3 per each group). A immunofluorescence results, a – f Pearson correlation scatterplot; B CD28 and B7-2 colocalization results. Data are expressed as Pearson correlation coefficient, Kruskal–Wallis one-way ANOVA test. ** p

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com



Results of CTLA-4 mRNA level and the correlation between CTLA-4 and B7-1 in spleen of immunosuppressed rats (n = 3–5 per each group). A immunofluorescence results, a – f Pearson correlation scatterplot; B CTLA-4 IOD results; C CTLA-4 mRNA level; D B7-1 mRNA level; E CTLA- and B7-1 colocalization results. Data are expressed as means ± SD, One-way ANOVA tests with LSD-t post-hoc tests executed and Pearson correlation coefficient, Kruskal–Wallis one-way ANOVA test. * p



Results of the correlation between CTLA-4 and B7-2 in spleen of immunosuppressed rats (n = 3 per each group). A immunofluorescence results, a – f Pearson correlation scatterplot; B CTLA-4 and B7-2 colocalization results. Data are expressed as Pearson correlation coefficient, Kruskal–Wallis one-way ANOVA test. ## p



Western blot analysis of CTLA4 (CD152) expression in NIH/3T3 cell lysate.

Anti-CTLA4 (CD152) Monoclonal Antibody

For Research Use Only. Not for use in diagnostic procedures.